As the CRO flies

Successful treatment development relationships rely on the ability of contract research organisations to bring their skills to the table – and pharma’s willingness to let that happen
Biosimilar adalimumab: a landmark for NHS medicines optimisation

The implications of adalimumab’s European patent expiry

News

View all

Lilly files lasmiditan for migraine

Eli Lilly has filed an application in the US to market lasmiditan for the acute treatment of migraine with or without aura in adults.

15th November 2018

Entry closes as countdown to the competition & awards ceremony begins

Entry has now closed for the inaugural PharmaTimes Medical & Scientific Awards, join us at the gala dinner awards ceremony where our winners will be revealed.

14th November 2018

Priority review for Roche’s Tecentriq/Abraxane combo

US regulators are undertaking a priority review of Roche’s Tecentriq in combination with Abraxane for the treatment of triple-negative breast cancer.

14th November 2018

Australian pharma Phebra sets up UK operations

Australian pharma Phebra has set up operations in the UK with the establishment of a new wholly-owned subsidiary company.

14th November 2018

NHS to fund continuous blood glucose monitoring system

Tens of thousands of people with type I diabetes across the country are to benefit from “life-changing” glucose monitors on the NHS, NHS England has announced on World Diabetes Day.

14th November 2018

Web Exclusives

View all

Taking a ‘big data’ view of regulatory information management

For pharmaceutical and life sciences firms, a case-by-case approach to information and content management has been prevalent for too long

A new age of virtual trials?

We spoke to Medidata’s General Manager and Senior Vice President EMEA Christian Hebenstreit at the New York NEXT conference to find out how virtual trials could change R&D

Why EU clinical trials are missing results

Tips for becoming compliant

Navigating an evolving bribery and corruption compliance regime

A review of the UK Bribery Act could mean pharma needs to adapt to changes in legislation

Magazine

View more from the latest edition

As the CRO flies

Successful treatment development relationships rely on the ability of contract research organisations to bring their skills to the table – and pharma’s willingness to let that happen

Biosimilar adalimumab: a landmark for NHS medicines optimisation

The implications of adalimumab’s European patent expiry

Precision medicine: optimising access

The new models that could help the industry encourage the adoption of personalised treatments

Precision medicine: overcoming cost challenges

Personalised treatments may be well-established in pharma now, but high prices continue to stymie their reach

Company focus: VistaGen

CEO Shawn Singh explains how his company hopes to change the treatment landscape for depression with an alternative to ketamine

Organs on a chip

This new innovation could be a paradigm shift for clinical trials, but it’s not without issues

RWE meets social media

We speak to Orbital Media’s CEO Peter Brady to find out how his company is taking a new approach to gathering data on how medicines fare in the real world

The future of multichannel

Wunderman Health EMEA lead Mo Zouina and Wunderman Health Global client lead Cassandra Sinclair give their views on the new technologies and practices that could change marketing in the near future